Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.48 |
| ▸ | FADS1 | O60427 | 5/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896688 | 0.85 | GRM2 (0.49) | GRM2FADS1HTR2A | |
| SCHEMBL2898909 | 0.85 | GRM2 (0.54) | GRM2FADS1HTR2AMMP1MMP13 | |
| SCHEMBL2893979 | 0.85 | GRM2 (0.54) | GRM2FADS1HTR2AMMP1MMP13 | |
| SCHEMBL2899915 | 0.85 | GRM2 (0.54) | GRM2FADS1HTR2AMMP1MMP13 | |
| Ethylamine SCHEMBL2896685 | 0.83 | GRM2 (0.52) | GRM2FADS1HTR2A | |
| SCHEMBL8233934 | 0.81 | GRM2 (0.52) | GRM2FADS1HTR2AMMP1MMP13 | |
| SCHEMBL2901406 | 0.80 | GRM2 (0.48) | GRM2FADS1HTR2AMMP1MMP13 | |
| SCHEMBL2900121 | 0.80 | GRM2 (0.56) | GRM2FADS1HTR2A | |
| SCHEMBL2894128 | 0.79 | GRM2 (0.50) | GRM2FADS1HTR2A | |
| SCHEMBL8235042 | 0.79 | GRM2 (0.49) | GRM2FADS1HTR2AMMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | GRM2 3/4885FADS1 4353/4885HTR2A 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.